Neuroscience imaging company IXICO plc (AIM: IXI) announced on Monday that it has entered into a commercial agreement with PETNET Solutions Inc, a Siemens Healthineers company. The agreement will see PETNET supply diagnostic imaging agents to IXICO, supporting the company's growing portfolio of clinical trials in neurological disorders.

This deal enhances IXICO's Tracer Management service, enabling the seamless integration of PET tracers into neurological clinical trials. PETNET's radioactive tracers are essential for Positron Emission Tomography (PET) scans, which are used to create detailed brain images. These tracers are particularly useful in assessing β-amyloid plaques and tau neurofibrillary tangles, which are key markers in the evaluation of Alzheimer's Disease and other cognitive disorders.

The agreement follows several key commercial milestones for IXICO in 2024, including contracts in Huntington's disease, Parkinson's disease and Alzheimer's disease clinical trials, as well as partnerships for MRI and PET tracer supply.

IXICO leverages AI-driven platforms to provide valuable insights into neuroscience, supporting pharmaceutical companies in advancing investigational therapies for central nervous system (CNS) disorders. Through its remote access technology, IXICO aims to reduce risk and uncertainty in clinical trials, improving the ROI for drug development.